Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0195 | ||||
| Gene Name | SLC25A33 | ||||
| Protein Name | Bone marrow stromal cell mitochondrial carrier protein | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
| Synonyms | BMSC-MCP; HuBMSC-MCP; PNC1; Protein PNC1; SLC25A33; Solute carrier family 25 member 33 | ||||
| DT Family | Mitochondrial Carrier (MC) Family ; | ||||
| Tissue Specificity | Expressed in the central nervous system. Alsoexpressed in testis and skeletal muscle. Weakly expressed inheart, liver, kidney, prostate, colon and peripheral bloodleukocytes. | ||||
| Function | This transporter is mitochondrial transporter that imports/exports pyrimidine nucleotides into and from mitochondria. Transports preferentially uracil, thymine, and cytosine (deoxy)nucleoside di- and triphosphates by an antiport mechanism. Also transports guanine but not adenine (deoxy)nucleotides. | ||||
| Endogenous Substrate(s) | Pyrimidines | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.